(NASDAQ: HBIO) Harvard Bioscience's forecast annual revenue growth rate of 4.77% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 6.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 144.27%.
Harvard Bioscience's revenue in 2026 is $86,550,000.On average, 4 Wall Street analysts forecast HBIO's revenue for 2026 to be $405,511,019, with the lowest HBIO revenue forecast at $388,293,861, and the highest HBIO revenue forecast at $418,846,490.
In 2027, HBIO is forecast to generate $440,177,877 in revenue, with the lowest revenue forecast at $422,916,000 and the highest revenue forecast at $453,146,645.